Marshall Wace, LLP Equillium, Inc. Transaction History
Marshall Wace, LLP
- $90.8 Billion
- Q3 2025
A detailed history of Marshall Wace, LLP transactions in Equillium, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 41,220 shares of EQ stock, worth $42,044. This represents 0.0% of its overall portfolio holdings.
Number of Shares
41,220Holding current value
$42,044% of portfolio
0.0%Shares
2 transactions
Others Institutions Holding EQ
# of Institutions
44Shares Held
32.3MCall Options Held
152KPut Options Held
0-
Adar1 Capital Management, LLC Austin, TX5.56MShares$5.67 Million0.75% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.33MShares$5.44 Million0.01% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.45MShares$4.54 Million1.82% of portfolio
-
Decheng Capital LLC Menlo Park, CA4.45MShares$4.54 Million1.11% of portfolio
-
Woodline Partners LP San Francisco, CA3.51MShares$3.58 Million0.03% of portfolio
About Equillium, Inc.
- Ticker EQ
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,352,100
- Market Cap $35M
- Description
- Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which i...